Florence Le Maulf

6.2k total citations · 1 hit paper
19 papers, 1.3k citations indexed

About

Florence Le Maulf is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Florence Le Maulf has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 4 papers in Physiology and 3 papers in Surgery. Recurrent topics in Florence Le Maulf's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers), Lipoproteins and Cardiovascular Health (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Florence Le Maulf is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers), Lipoproteins and Cardiovascular Health (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Florence Le Maulf collaborates with scholars based in United States, United Kingdom and Germany. Florence Le Maulf's co-authors include Nuala Peter, Ajay K. Kakkar, Jeffrey Friedman, Samuel Z. Goldhaber, Anita Vedel Christiansen, Patrick Mismetti, Sam Schulman, Sebastian Schellong, Clive Kearon and Henry Eriksson and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Florence Le Maulf

19 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

2013 688 citations Sam Schulman, Ajay K. Kakkar et al. Circulation profile →

Peers

Countries citing papers authored by Florence Le Maulf

Since Specialization

Citations

This map shows the geographic impact of Florence Le Maulf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Le Maulf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Le Maulf more than expected).

Fields of papers citing papers by Florence Le Maulf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Le Maulf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Le Maulf. The network helps show where Florence Le Maulf may publish in the future.

Co-authorship network of co-authors of Florence Le Maulf

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Le Maulf. A scholar is included among the top collaborators of Florence Le Maulf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Le Maulf. Florence Le Maulf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease 2017 ·BMJ Open Respiratory Research ·Kevin Flaherty, Kevin M. Brown, Athol U. Wells, Emmanuelle Clerisme-Beaty, Harold R. Collard, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Florence Le Maulf, Luca Richeldi, Hendrik Schmidt, Simon Walsh, William S. Mezzanotte, Rozsa Schlenker‐Herceg	134
2	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria 2016 ·American Journal of Respiratory and Critical Care Medicine ·Ganesh Raghu, Athol U. Wells, Andrew G. Nicholson, Luca Richeldi, Kevin Flaherty, Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker‐Herceg, David M. Hansell	127
3	Tiotropium Respimat® in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials 2015 ·Journal of Cystic Fibrosis ·Félix Ratjen, Paul Koker, David E. Geller, (unknown), Florence Le Maulf, Sabine Kattenbeck, Petra Moroni-Zentgraf, J.S. Elborn	9
4	Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF) 2015 ·Pneumologie ·(unknown), Luca Richeldi, J. Alberto San Román, Florence Le Maulf, Christoph Hallmann, Susanne Stowasser, (unknown)	3
5	S106 Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in IPF 2015 ·Thorax ·Ganesh Raghu, Athol U. Wells, (unknown), Luca Richeldi, (unknown), Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker‐Herceg, D.M. Hansell	5
6	Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib 2015 ·Vincent Cottin, Huiping Li, Fabrizio Luppi, Florence Le Maulf, Rozsa Schlenker‐Herceg, Susanne Stowasser, Roland M. du Bois	2
7	Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis 2014 ·Respiratory Medicine ·Luca Richeldi, Vincent Cottin, Kevin Flaherty, Martin Kolb, Yoshikazu Inoue, Ganesh Raghu, Hiroyuki Taniguchi, David M. Hansell, Andrew G. Nicholson, Florence Le Maulf, Susanne Stowasser, Harold R. Collard	73
8	64 Tiotropium in cystic fibrosis: Pooled analysis of phase II and III randomized, controlled trials 2013 ·Journal of Cystic Fibrosis ·David E. Geller, Paul Koker, J.S. Elborn, Florence Le Maulf, Sabine Kattenbeck, (unknown), Félix Ratjen	3
9	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation 2013 ·Cancer ·Eunice L. Kwak, Geoffrey I. Shapiro, Seth M. Cohen, Carlos Becerra, Heinz‐Josef Lenz, Wen‐Fang Cheng, Wu‐Chou Su, (unknown), Florence Le Maulf, Maximilian T. Lobmeyer, Vikram K. Chand, A. John Iafrate	16
10	Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis breakdown → 2013 ·Circulation ·Sam Schulman, Ajay K. Kakkar, Samuel Z. Goldhaber, Sebastian Schellong, Henry Eriksson, Patrick Mismetti, Anita Vedel Christiansen, Jeffrey Friedman, Florence Le Maulf, Nuala Peter, Clive Kearon	688
11	61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial 2013 ·Journal of Cystic Fibrosis ·Félix Ratjen, Paul Koker, David E. Geller, (unknown), Florence Le Maulf, Sabine Kattenbeck, (unknown), J.S. Elborn	3
12	Japanese Guideline on Global Clinical Trials: Statistical Implications and Alternative Criteria for Assessing Consistency 2011 ·Drug Information Journal ·Kevin J. Carroll, Florence Le Maulf	4
13	Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors 2009 ·Journal of Clinical Oncology ·Marlies H.G. Langenberg, Carla M.L. van Herpen, Johann S. de Bono, Jan H.M. Schellens, Clemens Unger, Klaas Hoekman, Hubert E. Blum, Walter Fiedler, Joachim Drevs, Florence Le Maulf, Anitra Fielding, Jane Robertson, Emile E. Voest	81
14	Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib 2008 ·Journal of Clinical Oncology ·Marlies H.G. Langenberg, Carla M. van Herpen, Johann S. de Bono, Christine Unger, Jan H.M. Schellens, K. Hoekman, (unknown), Florence Le Maulf, Anitra Fielding, Emile E. Voest	14
15	Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins 2007 ·The American Journal of Cardiology ·Bela F. Asztalos, Florence Le Maulf, (unknown), Evan A. Stein, Peter H. Jones, Katalin V. Horvath, Fergus McTaggart, Ernst J. Schaefer	69
16	Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia 2007 ·The American Journal of Cardiology ·Evan A. Stein, John Amerena, Christie M. Ballantyne, (unknown), Michel Farnier, Robert Guthrie, Dror Harats, (unknown), Florence Le Maulf, Helena Melezínková, Alex Gold, Philip T. Sager	25
17	Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia 2007 ·Journal of clinical lipidology ·Evan A. Stein, A. David Marais, Jean Ducobu, Michel Farnier, Dov Gavish, Hans Hauner, Andrew J. Kaplan, Florence Le Maulf, Helena Melezínková	7
18	W16-O-003 Efficacy and safety of rosuvastatin 40 MG in patients with severe type IIA and IIB hypercholesterolaemia 2005 ·Atherosclerosis Supplements ·Evan A. Stein, Helena Melezínková, Florence Le Maulf, Alex Gold	3
19	76 ZD4054: assessment of endothelin A receptor specificity following single dose administration in healthy volunteers 2004 ·European Journal of Cancer Supplements ·(unknown), David J. Wilson, (unknown), Florence Le Maulf, (unknown), Rainard Fuhr	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact